調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

In Vivo Toxicology Market by Product (Instruments, Consumables (Animal models, Reagents & Kits)), Testing type (Chronic, Sub-chronic), Toxicity Endpoints (Immunotoxicity, Systemic, DART), Testing Facility (Outsourced, In-house) - Global Forecast to 2022

体内 (in vivo) 毒性の世界市場予測（～2022年）：商品別（器機、消耗品（動物モデル、試薬と道具））、テストタイプ別（慢性、亜慢性）、毒性評価項目別（免疫毒性、全身毒性、発生・生殖毒性）、テスト施設別（外部委託、社内）

◆タイトル：In Vivo Toxicology Market by Product (Instruments, Consumables (Animal models, Reagents & Kits)), Testing type (Chronic, Sub-chronic), Toxicity Endpoints (Immunotoxicity, Systemic, DART), Testing Facility (Outsourced, In-house) - Global Forecast to 2022
◆商品コード：MAM-BT-6000
◆調査・発行会社：MarketsandMarkets
◆発行日：2018年2月14日
◆ページ数：198
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：バイオ技術
◆販売価格オプション（消費税別）

Single User（1名利用）	USD5,650 ⇒換算￥615,850	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥724,850	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥888,350	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、体内 (in vivo) 毒性の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、種類別分析、セグメント別分析、地域別分析、体内 (in vivo) 毒性の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・体内 (in vivo) 毒性市場：商品別
・体内 (in vivo) 毒性市場：テストタイプ別
・体内 (in vivo) 毒性市場：毒性評価項目別
・体内 (in vivo) 毒性市場：テスト施設別
・体内 (in vivo) 毒性市場：地域別
・競争状況
・企業プロファイル
・付録

“The global in vivo toxicology market is projected to grow at a CAGR of 6.9%.”
The in vivo toxicology market is expected to reach USD 6.14 billion by 2022 from an estimated USD 4.40 billion in 2017, at a CAGR of 6.9%. The key factors driving the growth of this market include, increasing pharmaceutical R&D activities, mandatory government regulations for animal testing, innovations in animal models, and the development of exclusive in vivo toxicology tests. On the other hand, alternative methods to animal testing and disadvantages associated with animal toxicology testing likely to restrain the growth of this market.

“The instruments segment is expected to grow at the highest CAGR during the forecast period”
On the basis of product, the in vivo toxicology market is segmented into consumables and instruments. The consumables segment is further divided into reagents & kits and animal models. The instruments segment is expected to grow at the highest rate during the forecast period. The growth of this segment can be attributed to the increasing research on biological samples (such as blood and urine) using bioanalytical equipment.

“Chronic toxicity testing holds the largest share in the global in vivo toxicology market by testing type”
Based on testing type, the global in vivo toxicology market is segmented into acute, sub-acute, sub-chronic, and chronic toxicity testing. In 2017, chronic toxicity testing segment is estimated to hold the largest share in the global in vivo toxicology market. The large share of this market is attributed to the high cost of in vivo testing for more than 90 days, maintaining the animals, quality of tests, and the long duration of the tests performed.

“The immunotoxicity segment is expected to grow at the highest CAGR during the forecast period.”
On the basis of toxicity endpoint, the global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental and reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2017, the immunotoxicity segment is expected to account for the largest share in the in vivo toxicology market, this segment is also expected to grow at the highest CAGR during the forecast period. Rising demand for the development of biologics for autoimmune diseases and cancer and the increasing growth of biosimilars in oncology are driving the growth of this segment.

“China to witness the highest growth in the APAC region during the forecast period (2017-2022)”
In the APAC region, China is expected to witness the highest growth during the study period. The rising R&D funding and collaborations; initiatives taken by the Chinese government to promote life science research; and the strong trend of commercialization of biotechnology research are contributing to the growth of in vivo toxicology market in China.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–29%, Tier 2–35% and Tier 3–36%
• By Designation – C-level–39%, Director Level–35%, Others–26%
• By Region – North America–42%, Europe–36%, Asia Pacific–13%, RoW–9%

The major players in the global in vivo toxicology market are Thermo Fisher (US), Danaher (US), Charles River (US), Covance (LabCorp), and The Jackson Laboratory (US).
Research Coverage:
The report analyzes the in vivo toxicology market and aims at estimating the market size and future growth potential of this market based on various aspects such as products, testing type, toxicity endpoint, testing facility and region. The report also includes the competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in-turn would help them, garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by key players in the global in vivo toxicology market. The report analyzes the global in vivo toxicology market by product, testing type, toxicity endpoint, testing facility, and region
• Product and Service Innovation: Detailed insights on upcoming trends and product and service launches in the global in vivo toxicology market
• Market Development: Comprehensive information about the lucrative emerging markets by product, testing type, toxicity endpoint, testing facility, and region
• Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global in vivo toxicology market
• Competitive Assessment: In-depth assessment of market shares and growth strategies of leading players in the global market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.4 YEARS CONSIDERED FOR THE STUDY 16
1.5 CURRENCY 17
1.6 LIMITATIONS 17
1.7 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 RESEARCH DATA 18
2.2 MARKET RANKING 20
2.2.1 SECONDARY DATA 20
2.2.1.1 Secondary sources 20
2.2.2 PRIMARY DATA 21
2.2.2.1 Key data from Primary sources 21
2.2.2.2 Key industry insights 22
2.3 MARKET SIZE ESTIMATION 23
2.3.1 BOTTOM-UP APPROACH 23
2.3.2 TOP-DOWN APPROACH 24
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 25
2.5 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 31
4.1 ATTRACTIVE OPPORTUNITIES IN THE IN VIVO TOXICOLOGY MARKET 31
4.2 IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE 31
4.3 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT AND BY COUNTRY/REGION 32
4.4 IN VIVO TOXICOLOGY MARKET: DEVELOPING VS. DEVELOPED COUNTRIES 32
4.5 GLOBAL IN VIVO TOXICOLOGY MARKET: GEOGRAPHIC SNAPSHOT 33
5 MARKET OVERVIEW 34
5.1 INTRODUCTION 34
5.2 MARKET DYNAMICS 34
5.2.1 DRIVERS 35
5.2.1.1 Increasing pharmaceutical R&D activities 35
5.2.1.2 Mandatory government regulations for animal testing 36
5.2.1.3 Innovations in animal models 36
5.2.1.4 Exclusive in vivo toxicology tests 37
5.2.2 RESTRAINTS 38
5.2.2.1 Alternative methods to animal testing 38
5.2.2.2 Disadvantages associated with animal toxicology testing 38
5.2.3 OPPORTUNITIES 39
5.2.3.1 Increasing research in oncology and personalized medicine 39
5.2.3.2 Rising demand for humanized animal models 39
5.2.4 CHALLENGES 40
5.2.4.1 Regulations and laws for the ethical use of animals in research 40
6 IN VIVO TOXICOLOGY MARKET, BY PRODUCT 41
6.1 INTRODUCTION 42
6.2 CONSUMABLES 43
6.2.1 REAGENTS & KITS 44
6.2.2 ANIMAL MODELS 45
6.2.2.1 Mice models 46
6.2.2.2 Rat models 48
6.2.2.3 Other animal models 49
6.3 INSTRUMENTS 51
7 IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE 53
7.1 INTRODUCTION 54
7.2 CHRONIC TOXICITY TESTING 55
7.3 SUB-CHRONIC TOXICITY TESTING 56
7.4 SUB-ACUTE TOXICITY TESTING 57
7.5 ACUTE TOXICITY TESTING 58
8 IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT 60
8.1 INTRODUCTION 61
8.2 IMMUNOTOXICITY 62
8.3 SYSTEMIC TOXICITY 63
8.4 CARCINOGENICITY 64
8.5 GENOTOXICITY 66
8.6 DEVELOPMENTAL AND REPRODUCTIVE TOXICITY (DART) 67
8.7 OTHER TOXICITY ENDPOINTS 68

9 IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY 70
9.1 INTRODUCTION 71
9.2 OUTSOURCED TESTING FACILITIES 72
9.3 IN-HOUSE TESTING FACILITIES 74
10 IN VIVO TOXICOLOGY MARKET, BY REGION 76
10.1 INTRODUCTION 77
10.2 NORTH AMERICA 78
10.2.1 US 82
10.2.2 CANADA 87
10.3 EUROPE 90
10.3.1 GERMANY 95
10.3.2 UK 98
10.3.3 FRANCE 102
10.3.4 REST OF EUROPE (ROE) 105
10.4 ASIA PACIFIC 110
10.4.1 JAPAN 114
10.4.2 CHINA 118
10.4.3 INDIA 122
10.4.4 REST OF ASIA PACIFIC 126
10.5 LATIN AMERICA 130
10.6 MIDDLE EAST & AFRICA 134
11 COMPETITIVE LANDSCAPE 138
11.1 OVERVIEW 138
11.2 RANKING OF PLAYERS 139
11.3 MARKET SHARE ANALYSIS 140
11.4 COMPETITIVE SCENARIO 142
11.4.1 PRODUCT & SERVICE LAUNCHES 142
11.4.2 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS 142
11.4.3 ACQUISITIONS AND MERGERS 143
11.4.4 EXPANSIONS 143
11.4.5 OTHER DEVELOPMENTS 144

12 COMPANY PROFILES 145
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View)*
12.1 THERMO FISHER SCIENTIFIC 145
12.2 DANAHER 150
12.3 CHARLES RIVER LABORATORIES 155
12.4 LABCORP 159
12.5 THE JACKSON LABORATORY 163
12.6 DATA SCIENCES INTERNATIONAL 167
12.7 ENVIGO 169
12.8 EUROFINS SCIENTIFIC 172
12.9 PERKINELMER 176
12.10 SRI INTERNATIONAL 179
12.11 TACONIC BIOSCIENCES 182
12.12 WUXI APPTEC 184
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View might not be captured in case of unlisted companies.
13 APPENDIX 187
13.1 INSIGHTS OF INDUSTRY EXPERTS 187
13.2 DISCUSSION GUIDE 188
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 191
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 193
13.5 RELATED REPORTS 195
13.6 AUTHOR DETAILS 196

LIST OF TABLES

TABLE 1 INNOVATIVE ANIMAL MODELS DEVELOPED AND LAUNCHED BY PLAYERS 37
TABLE 2 REGULATORY AUTHORITIES OVERSEEING THE USE OF ANIMAL MODELS IN RESEARCH 40
TABLE 3 IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 42
TABLE 4 IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 43
TABLE 5 IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 43
TABLE 6 REAGENTS & KITS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 44
TABLE 7 ANIMAL MODELS MARKET, BY TYPE, 2015–2022 (USD MILLION) 45
TABLE 8 ANIMAL MODELS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 46
TABLE 9 MICE MODELS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 47
TABLE 10 RAT MODELS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 48
TABLE 11 OTHER ANIMAL MODELS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 50
TABLE 12 IN VIVO TOXICOLOGY INSTRUMENTS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 52
TABLE 13 IN VIVO TOXICOLOGY MARKET, BY TYPE, 2015–2022 (USD MILLION) 55
TABLE 14 CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 56
TABLE 15 SUB-CHRONIC TOXICITY TESTING MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 57
TABLE 16 SUB-ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 58
TABLE 17 ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 59
TABLE 18 IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2015–2022 (USD MILLION) 62
TABLE 19 IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY, BY COUNTRY,
2015–2022 (USD MILLION) 63
TABLE 20 IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY, BY COUNTRY,
2015–2022 (USD MILLION) 64
TABLE 21 IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY, BY COUNTRY,
2015–2022 (USD MILLION) 65
TABLE 22 IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY, BY COUNTRY,
2015–2022 (USD MILLION) 67
TABLE 23 IN VIVO TOXICOLOGY MARKET FOR DEVELOPMENTAL AND REPRODUCTIVE TOXICITY, BY COUNTRY, 2015–2022 (USD MILLION) 68
TABLE 24 IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS, BY COUNTRY, 2015–2022 (USD MILLION) 69
TABLE 25 IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2015–2022 (USD MILLION) 72
TABLE 26 IN VIVO TOXICOLOGY MARKET FOR OUTSOURCED TESTING FACILITIES,
BY COUNTRY, 2015–2022 (USD MILLION) 73
TABLE 27 IN VIVO TOXICOLOGY MARKET FOR IN-HOUSE TESTING FACILITIES, BY COUNTRY, 2015–2022 (USD MILLION) 75
TABLE 28 IN VIVO TOXICOLOGY MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 78
TABLE 29 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 80
TABLE 30 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 80
TABLE 31 NORTH AMERICA: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT, 2015–2022 (USD MILLION) 80
TABLE 32 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2015–2022 (USD MILLION) 81
TABLE 33 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 81
TABLE 34 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 82
TABLE 35 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 82
TABLE 36 NIH FUNDING FOR PROJECTS RELATED TO ANIMAL MODELS 83
TABLE 37 US: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 84
TABLE 38 US: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 85
TABLE 39 US: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 85
TABLE 40 US: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE, 2015–2022 (USD MILLION) 86
TABLE 41 US: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 86
TABLE 42 US: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 87
TABLE 43 CANADA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 88
TABLE 44 CANADA: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 88
TABLE 45 CANADA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 89
TABLE 46 CANADA: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 89
TABLE 47 CANADA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 90
TABLE 48 CANADA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 90
TABLE 49 EUROPE: IN VIVO TOXICOLOGY MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 92
TABLE 50 EUROPE: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 92
TABLE 51 EUROPE: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 92
TABLE 52 EUROPE: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 93
TABLE 53 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 93
TABLE 54 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 94
TABLE 55 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 94
TABLE 56 GERMANY: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 96
TABLE 57 GERMANY: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 96
TABLE 58 GERMANY: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 96
TABLE 59 GERMANY: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 97
TABLE 60 GERMANY: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 97
TABLE 61 GERMANY: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 98
TABLE 62 UK: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 99
TABLE 63 UK: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 100
TABLE 64 UK: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 100
TABLE 65 UK: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE, 2015–2022 (USD MILLION) 101
TABLE 66 UK: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 101
TABLE 67 UK: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 102
TABLE 68 FRANCE: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 103
TABLE 69 FRANCE: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 103
TABLE 70 FRANCE: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 103
TABLE 71 FRANCE: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 104
TABLE 72 FRANCE: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 104
TABLE 73 FRANCE: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 105
TABLE 74 ROE: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 108
TABLE 75 ROE: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 108
TABLE 76 ROE: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 108
TABLE 77 ROE: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE, 2015–2022 (USD MILLION) 109
TABLE 78 ROE: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 109
TABLE 79 ROE: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 110
TABLE 80 APAC: IN VIVO TOXICOLOGY MARKET, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 112
TABLE 81 APAC: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 112
TABLE 82 APAC: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 112
TABLE 83 APAC: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 113
TABLE 84 APAC: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 113
TABLE 85 APAC: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 114
TABLE 86 APAC: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 114
TABLE 87 RESEARCH COLLABORATIONS BY FOREIGN-AFFILIATED COMPANIES AND JAPANESE UNIVERSITIES/RESEARCH INSTITUTES (2016) 115
TABLE 88 JAPAN: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 116
TABLE 89 JAPAN: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 116
TABLE 90 JAPAN: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 117
TABLE 91 JAPAN: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 117
TABLE 92 JAPAN: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 118
TABLE 93 JAPAN: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 118
TABLE 94 CHINA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 119
TABLE 95 CHINA: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 120
TABLE 96 CHINA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 120
TABLE 97 CHINA: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 121
TABLE 98 CHINA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 121
TABLE 99 CHINA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 122
TABLE 100 INDIA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 124
TABLE 101 INDIA: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 124
TABLE 102 INDIA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 124
TABLE 103 INDIA: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 125
TABLE 104 INDIA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 125
TABLE 105 INDIA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 126
TABLE 106 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 127
TABLE 107 ROAPAC: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT,
2015–2022 (USD MILLION) 128
TABLE 108 ROAPAC: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE,
2015–2022 (USD MILLION) 128
TABLE 109 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 128
TABLE 110 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 129
TABLE 111 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 129
TABLE 112 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 132
TABLE 113 LATIN AMERICA: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT, 2015–2022 (USD MILLION) 132
TABLE 114 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2015–2022 (USD MILLION) 132
TABLE 115 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 133
TABLE 116 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2015–2022 (USD MILLION) 133
TABLE 117 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2015–2022 (USD MILLION) 134
TABLE 118 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,
2015–2022 (USD MILLION) 135
TABLE 119 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY CONSUMABLES MARKET, BY SEGMENT, 2015–2022 (USD MILLION) 135
TABLE 120 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS,
BY TYPE, 2015–2022 (USD MILLION) 135
TABLE 121 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE,
2015–2022 (USD MILLION) 136
TABLE 122 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2015–2022 (USD MILLION) 136
TABLE 123 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2015–2022 (USD MILLION) 137
TABLE 124 RANK OF COMPANIES IN THE IN VIVO TOXICOLOGY MARKET,
BY INSTRUMENTS, 2017 139

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 18
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY SIZE, DESIGNATION,
AND REGION 22
FIGURE 3 MARKET DATA TRIANGULATION METHODOLOGY 25
FIGURE 4 IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2017 VS. 2022 (USD BILLION) 27
FIGURE 5 IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE, 2017 VS. 2022 (USD BILLION) 28
FIGURE 6 IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,
2017 VS. 2022 (USD BILLION) 28
FIGURE 7 IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,
2017 VS. 2022 (USD BILLION) 29
FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE IN VIVO TOXICOLOGY MARKET 30
FIGURE 9 INCREASING PHARMACEUTICAL R&D ACTIVITIES AND MANDATORY GOVERNMENT REGULATIONS FOR ANIMAL TESTING TO DRIVE MARKET GROWTH 31
FIGURE 10 CHRONIC TESTING SEGMENT TO COMMAND THE LARGEST SHARE IN THE
MARKET IN 2017 31
FIGURE 11 IMMUNOTOXICITY SEGMENT TO COMMAND THE LARGEST SHARE IN THE EUROPEAN MARKET IN 2017 32
FIGURE 12 DEVELOPING COUNTRIES TO GROW AT THE HIGHEST RATE FROM 2017 TO 2022 32
FIGURE 13 CHINA TO REGISTER HIGHEST GROWTH DURING THE FORECAST PERIOD 33
FIGURE 14 IN VIVO TOXICOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 34
FIGURE 15 PHARMACEUTICAL R&D EXPENDITURE IN THE US, EUROPE, AND JAPAN
(2000—2015) 35
FIGURE 16 CONSUMABLES SEGMENT WILL CONTINUE TO DOMINATE THE IN VIVO TOXICOLOGY MARKET DURING THE FORECAST PERIOD 42
FIGURE 17 CHRONIC TOXICITY TESTING SEGMENT WILL CONTINUE TO DOMINATE THE IN VIVO TOXICOLOGY MARKET IN 2022 54
FIGURE 18 IMMUNOTOXICITY SEGMENT WILL CONTINUE TO DOMINATE THE IN VIVO TOXICOLOGY MARKET IN 2022 61
FIGURE 19 OUTSOURCED TESTING FACILITIES WILL CONTINUE TO DOMINATE THE IN VIVO TOXICOLOGY MARKET IN 2022 71
FIGURE 20 IN VIVO TOXICOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 77
FIGURE 21 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET SNAPSHOT 79
FIGURE 22 EUROPE: IN VIVO TOXICOLOGY MARKET SNAPSHOT 91
FIGURE 23 NUMBER OF CELL THERAPY PRECLINICAL STUDIES IN THE UK (2013–2016) 99
FIGURE 24 ROE COUNTRIES: PHARMACEUTICAL INDUSTRY R&D EXPENDITURE (2015) 105
FIGURE 25 APAC: IN VIVO TOXICOLOGY MARKET SNAPSHOT 111
FIGURE 26 INDIA: R&D SPENDING BY TOP PHARMA GIANTS IN FY 2016 123
FIGURE 27 LATAM: IN VIVO TOXICOLOGY MARKET SNAPSHOT 131
FIGURE 28 COMPANIES ADOPTED PRODUCT & SERVICE LAUNCHES AS THEIR KEY GROWTH STRATEGY OVER THE LAST THREE YEARS 138
FIGURE 29 GLOBAL ANIMAL MODELS MARKET SHARE, BY KEY PLAYER, 2016 140
FIGURE 30 GLOBAL IN VIVO TOXICOLOGY SERVICES (CRO) MARKET SHARE,
BY KEY PLAYER, 2016 141
FIGURE 31 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 145
FIGURE 32 DANAHER: COMPANY SNAPSHOT 150
FIGURE 33 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 155
FIGURE 34 LABCORP: COMPANY SNAPSHOT 159
FIGURE 35 THE JACKSON LABORATORY: COMPANY SNAPSHOT 163
FIGURE 36 ENVIGO: COMPANY SNAPSHOT 169
FIGURE 37 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 172
FIGURE 38 PERKINELMER: COMPANY SNAPSHOT 176

★調査レポート[体内 (in vivo) 毒性の世界市場予測（～2022年）：商品別（器機、消耗品（動物モデル、試薬と道具））、テストタイプ別（慢性、亜慢性）、毒性評価項目別（免疫毒性、全身毒性、発生・生殖毒性）、テスト施設別（外部委託、社内）] ( In Vivo Toxicology Market by Product (Instruments, Consumables (Animal models, Reagents & Kits)), Testing type (Chronic, Sub-chronic), Toxicity Endpoints (Immunotoxicity, Systemic, DART), Testing Facility (Outsourced, In-house) - Global Forecast to 2022 / MAM-BT-6000) 販売に関する免責事項

[体内 (in vivo) 毒性の世界市場予測（～2022年）：商品別（器機、消耗品（動物モデル、試薬と道具））、テストタイプ別（慢性、亜慢性）、毒性評価項目別（免疫毒性、全身毒性、発生・生殖毒性）、テスト施設別（外部委託、社内）] ( In Vivo Toxicology Market by Product (Instruments, Consumables (Animal models, Reagents & Kits)), Testing type (Chronic, Sub-chronic), Toxicity Endpoints (Immunotoxicity, Systemic, DART), Testing Facility (Outsourced, In-house) - Global Forecast to 2022 / MAM-BT-6000) についてEメールでお問い合わせ

◆関連調査資料◆

デジタル保証の世界市場予測（～2022年）：テストモード別（手動テスト、自動テスト）、テストタイプ別（API、機能、ネットワーク、性能、セキュリティ、ユーザビリティテスト）、技術別（SMAC）、組織サイズ別、業種別、地域別
MAM-TC-5994 / MarketsandMarkets / 2018年2月13日 / MarketsandMarketsが発行した当調査レポートでは、デジタル保証の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、種類別分析、セグメント別分析、地域別分析、デジタル保証の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要と産業トレンド・デジタル保証市場：テストモード別・デジタル保証市場：テストタイプ別・デジタル保証市場：技術別・デジタル保証市場：組織サイズ別...The digital assurance market is projected to grow at a CAGR of 13.5% during the forecast period The digital assurance market size is expected to grow from USD 2.90 billion in 2017 to USD 5.47 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 13.5% during the forecast period. The growing need of Application Programming Interface (API) monitoring in the digital economy and the increasing use of agile and DevOps methodologies are some of the major drivers that are expected to increase the demand for digital assurance. Shadow IT is a major risk area for organizations and can...

インビトロ毒物検査の世界市場予測（～2022年）
MAM-BT-2373 / MarketsandMarkets / 2017年9月26日 / MarketsandMarketsが発行した当調査レポートでは、インビトロ毒物検査の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、製品・サービス別分析、毒性タイプ別分析、技術別分析、方法別分析、インビトロ毒物検査の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...“The global in vitro toxicology testing market is projected to grow at a CAGR of 6.6%.”The in vitro toxicology testing market is expected to reach USD 8.74 billion by 2022 from an estimated USD 6.34 billion in 2017, at a CAGR of 6.6%. The key factors driving the growth of this market include opposition to animal testing, growing demand for in vitro technology in the European market, new and promising technologies, and increasing R&D expenditure to detect toxicity at an early stage. On the other hand, failure to establish intricacies of in vivo conditions through in vitro, lack of in...

ヒト肝臓モデルの世界市場予測（～2022年）
BT6218 / MarketsandMarkets / 2018年4月26日 / 当調査レポートでは、ヒト肝臓モデルの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、創薬プラットフォーム別分析、地域別分析、ヒト肝臓モデルの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global human liver models market is projected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6%. The growth of this market is primarily driven by factors such as the growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to...

生体機能チップの世界市場予測（～2022年）：種類別（肝臓、腎臓、肺、心臓、腸、消化管）、提供物別（製品、サービス）、用途別（毒性試験、生理学的モデル）、エンドユーザー別（学術、研究機関、製薬会社）
MAM-BT-5883 / MarketsandMarkets / 2018年1月12日 / MarketsandMarketsが発行した当調査レポートでは、生体機能チップの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、生体機能チップの世界市場規模及び予測、セグメント別市場規模、市場動向、競争状況、関連企業分析などの情報をお届けいたします。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・生体機能チップ市場：種類別・生体機能チップ市場：提供物別・生体機能チップ市場：用途別・生体機能チップ市場：エンドユーザー別...The organs-on-chips market is expected to reach USD 45.6 Million by 2022 from USD 9.6 Million in 2017, at a CAGR of 36.6%. The growth of this market is mainly driven by the growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of organs-on-chips, technological advancements and new products launches, growing number of partnerships and collaborations between pharmaceutical companies and organs-on-chips manufacturers, and growing need for early detection of drug toxicity to minimize financial losses due to late stage drug failure. This report segments the organs-on-chips market into...

ヒト化マウスおよびラットモデルの世界市場予測（～2022年）
BT-4938 / MarketsandMarkets / 2018年3月22日 / MarketsandMarketsが発行した当調査レポートでは、ヒト化マウスおよびラットモデルの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、種類別分析、用途別分析、需要先別分析、地域別分析、ヒト化マウスおよびラットモデルの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The humanized mouse models market is projected to reach USD 128.9 Million by 2022 from USD 80.3 Million in 2017, at a CAGR of 9.9% during the forecast period. The humanized rat models market is expected to reach USD 8.9 Million by 2022 from USD 5.9 Million in 2017, at a CAGR of 8.4% during the forecast period. The key factors boosting market growth are increasing number of R&D activities in pharmaceutical and biotechnology companies, increasing number of research activities involving humanized models, continuous support in the form of investments and grants from the government and private sectors, and growing...

バイオシミュレーションの世界市場予測（～2022年）：ソフトウェア、分子シミュレーション、社内、契約サービス
MAM-HIT-3629 / MarketsandMarkets / 2018年1月3日 / MarketsandMarketsが発行した当調査レポートでは、バイオシミュレーションの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、製品別分析、用途別分析、需要先別分析、地域別分析、バイオシミュレーションの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global biosimulation market is projected to reach USD 2.88 Billion by 2022 from USD 1.38 Billion in 2017, at a CAGR of 15.9%. Factors such as increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of the market. The report segments the global biosimulation market into by product & service, application, delivery model, end user, and region. Based on product & service, the biosimulation market is...

試験管内肺モデルの世界市場予測（～2023年）
BT6203 / MarketsandMarkets / 2018年4月25日 / MarketsandMarketsが発行した当調査レポートでは、試験管内肺モデルの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、種類（2D、3D）別分析、用途別分析、地域別分析、試験管内肺モデルの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The lung in vitro models market is projected to reach USD 427.4 Million by 2023 from USD 190.5 Million in 2018, at a CAGR of 17.5%. The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, advancements in cell culture technologies, and the development of new 3D in vitro models. The report analyzes the lung in vitro models market by type, applications, and region. Based on type, the in vitro lung model market is segmented into 2D cell models and 3D cell models. 3D cell models is further segmented into in-house...

3D細胞培養の世界市場予測（～2022年）：足場材フリー（懸滴培養、バイオリアクタ）、マイクロ流体力学、磁気浮上
MAM-BT-4414 / MarketsandMarkets / 2017年11月8日 / MarketsandMarketsが発行した当調査レポートでは、3D細胞培養の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品種類別分析、用途別分析、需要先別分析、地域別分析、3D細胞培養の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global 3D cell culture market is projected to reach USD 1,720.3 Million by 2022 from USD 682.8 Million in 2017, at a CAGR of 20.3%. Factors such as rising focus on developing alternative methods for animal testing, funding initiatives from government and private investors, technological advancements and product launches, and growing awareness are driving the growth of the market. The report segments the global market into by type of product, application, end user, and region. Based on product, the market is segmented into scaffold-based 3D cell culture, scaffold-free 3D cell culture, microfluidics-based 3D cell culture, and magnetic levitation and...

患者腫瘍組織移植モデル（PDXモデル）の世界市場予測（～2022年）
MAM-BT5576 / MarketsandMarkets / 2017年9月14日 / MarketsandMarketsが発行した当調査レポートでは、患者腫瘍組織移植モデル（PDXモデル）の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、種類別分析、腫瘍タイプ別分析、用途別分析、需要先別分析、患者腫瘍組織移植モデル（PDXモデル）の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global PDX models market is expected to reach USD 167.6 Million by 2022 from USD 77.4 Million in 2017, at a CAGR of 16.7%. The growth of this market is majorly driven by the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. However, the high cost of personalized PDX models and stringent guidelines regarding the ethical use of animals in cancer research are expected to restrain the growth of this market during the forecast period. The report...

臨床検査サービスの世界市場予測（～2022年）
MAM-MD-5847 / MarketsandMarkets / 2017年12月21日 / MarketsandMarketsが発行した当調査レポートでは、臨床検査サービスの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、専門別分析、プロバイダー別分析、地域別分析、臨床検査サービスの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...Clinical laboratory services market projected to grow at a CAGR of 5.2% The clinical laboratory services market is projected to reach USD 146.14 billion by 2022 from USD 113.44 billion in 2017, at a CAGR of 5.2%. The increasing global burden of target diseases, advancements in clinical diagnostic techniques, and rising government initiatives to improve the quality and affordability of clinical diagnostic testing procedures are the major factors driving the demand for clinical laboratory services market. Factors such as the pricing pressure faced by healthcare payers and providers and the procedural shift from lab-based diagnosis to home-based/point-of-care testing procedures are...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆